Company: INDP
Filing Date: 2025-04-17
Form Type: PRE 14A
Source: 0001641172-25-005234
Chunk: 2

Company: Indaptus Therapeutics, Inc.
Filing Date: 2025-04-17
Form: PRE 14A
Chunk 2
---
      | 40 |
| CERTAIN RELATIONSHIPS AND RELATED PERSON TRANSACTIONS               | 42 |
| STOCKHOLDERS’ PROPOSALS                                             | 43 |
| OTHER MATTERS                                                       | 43 |
| SOLICITATION OF PROXIES                                             | 43 |
| INDAPTUS’ ANNUAL REPORT ON FORM 10-K                                | 44 |

| i |

<div align='center'>INDAPTUS THERAPEUTICS, INC.

3 Columbus Circle

New York, NY 10019

NOTICE OF ANNUAL MEETING OF STOCKHOLDERS

TO BE HELD Tuesday, JUNE 10, 2025</div>

The Annual Meeting of Stockholders (the “Annual Meeting”) of Indaptus Therapeutics, Inc., a Delaware corporation (the “Company”), will be held at 10:00 a.m. Eastern time on Tuesday, June 10, 2025, at the offices of Indaptus Therapeutics, Inc., 3 Columbus Circle, 15th Floor, New York, NY. The Annual Meeting will be held for the following purposes:

| ● 
 ● | To                                                                                                                                      
 elect Mark J. Gilbert, M.D., Hila Karah, and Robert E. Martell, M.D., Ph.D as Class I directors, to serve until the 2028 Annual Meeting 
 of Stockholders, and until their respective successors have been duly elected and qualified;                                            
 To                                                                                                                                      
 ratify the appointment of Haskell & White LLP as our independent registered public accounting firm for the fiscal year ending           
 December 31, 2025;                                                                                                                      |
|:--|:----------------------------------------------------------------------------------------------------------------------------------------|
| ● | To                                                                                                                                      
 approve, on an advisory basis, the compensation paid to our named executive officers;                                                   |
| ● | To                                                                                                                                      
 approve an amendment to our Amended and Restated Certificate of Incorporation, as amended, in the form set forth on Appendix A          
 attached to this Proxy Statement, to effect a reverse stock split (the “Reverse Stock Split”) with respect to our issued                
 and outstanding common stock, par value $0.01 per share, at a ratio of 1-for-5 to 1-for-28 (the “Range”), with the ratio                
 at which the Reverse Stock Split would be effected to be a ratio within the Range to be determined at the discretion of our Board       
 of Directors and included in a public announcement by the Company before the effectiveness of the Reverse Stock Split;